Meeting
2019 ASCO Annual Meeting
A randomized phase II study of durvalumab and tremelimumab compared to doxorubicin in patients with advanced or metastatic soft tissue sarcoma (MEDISARC, AIO-STS 0415).
Authors
Viktor Grünwald
Dept. Hematology, Hemostaseology, Oncology & Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
Viktor Grünwald , Sebastian Bauer , Barbara Hermes , Philipp Ivanyi , Lars H Lindner , Daniel Pink , Peter Reichardt , Stephan Richter , Armin Tuchscherer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
2016-004750-15
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS11075)
DOI
10.1200/JCO.2019.37.15_suppl.TPS11075
Abstract #
TPS11075
Poster Bd #
397b
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
The Canadian Cancer Trials Group PA.7 trial: Results from the safety run in of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) versus GEM, nab-P, durvalumab (D), and tremelimumab (T) as first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).
First Author: Daniel John Renouf
Poster
2018 Gastrointestinal Cancers Symposium
A randomized phase 2 study of durvalumab monotherapy and in combination with tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS study.
First Author: Eileen Mary O'Reilly
Poster
2024 ASCO Gastrointestinal Cancers Symposium
ADJUBIL: A phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in adjuvant situation for biliary tract cancer.
First Author: Thorsten Goetze
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Phase II study of the combination of durvalumab, tremelimumab, and paclitaxel as second-line chemotherapy in biomarker-selected patients with metastatic gastric cancer.
First Author: Keun-Wook Lee